Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 102

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 102
---
 tax— — — (41)— (41)Balance, June 30, 202556,119,360 56 496,946 (200)567,098 1,063,900 Share-based compensation expense related to employee stock purchase plan and share-based awards— — 7,825 — — 7,825 Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld999,793 1 22,929 — — 22,930 Net loss— — — — (45,117)(45,117)Unrealized gain on marketable securities, net of tax— — — 129 — 129 Balance, September 30, 202557,119,153 $57 $527,700 $(71)$521,981 $1,049,667 

See accompanying notes.

6

Supernus Pharmaceuticals, Inc.

Condensed Consolidated Statements of Changes in Stockholders' Equity 

(unaudited, in thousands, except share data)

Common StockAdditional Paid-in CapitalAccumulated OtherComprehensiveEarnings (Loss)RetainedEarningsTotalStockholders'EquitySharesAmountBalance, December 31, 202354,723,356 $55 $439,493 $(593)$482,561 $921,516 Share-based compensation expense related to employee stock purchase plan and share-based awards— — 5,897 — — 5,897 Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld241,960 — 1,570 — — 1,570 Net earnings— — — — 124 124 Unrealized gain on marketable securities, net of tax— — — 59 — 59 Balance, March 31, 202454,965,316 55 446,960 (534)482,685 929,166 Share-based compensation expense related to employee stock purchase plan and share-based awards— — 6,552 — — 6,552 Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld80,733 — 1,658 — — 1,658 Net earnings—